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Background: Previous studies have linked muscarinicM4 receptors (CHRM4) to schizophrenia.
Specifically, the rs2067482 polymorphism was found to be highly associated with this disease.
Purpose: To test whether rs2067482 and rs72910092 are potential risk factors for schizo-
phrenia and/or pharmacogenetic markers for antipsychotic-induced tardive dyskinesia.
Patients and Methods: We genotyped DNA of 449 patients with schizophrenia and 134
healthy controls for rs2067482 and rs72910092 polymorphisms of the CHRM4 gene with the
use of the MassARRAY® System by Agena Bioscience. Mann–Whitney test was used to
compare qualitative traits and χ2 test was used for categorical traits.
Results: The frequency of genotypes and alleles of rs72910092 did not differ between patients
with schizophrenia and control subjects. We did not reveal any statistical differences for both
rs2067482 and rs72910092 between schizophrenia patients with and without tardive dyskinesia.
The frequency of the C allele of the polymorphic variant rs2067482 was significantly higher in
healthy persons compared to patients with schizophrenia (OR=0.51, 95% CI [0.33–0.80];
p=0.003). Accordingly, the CC genotype was found significantly more often in healthy persons
compared to patients with schizophrenia (OR=0.49, 95% CI [0.31–0.80]; p=0.010).
Conclusion: Our study found the presence of the minor allele (T) of rs2067482 variant
being associated with schizophrenia. We argue that the association of rs2067482 with
schizophrenia may be via its regulatory effect on some other gene with protein kinase
C and casein Kknase substrate in neurons 3 (PACSIN3) as a possible candidate. Neither
rs2067482 nor rs72910092 is associated with tardive dyskinesia.
Keywords: schizophrenia, suicide, tardive dyskinesia, PACSIN3, CHRM4, gene polymorphism
Introduction
Schizophrenia is a severe mental illness which often leads to significant long-term social
or occupational disability of affected patients. The disease is characterized by positive
symptoms such as delusions, hallucinations, and psychomotor agitationwith hostility, but
also by blunted and inadequate affect, concretisms, planning difficulties and many other
negative and cognitive symptoms.1,2 The aetiology of schizophrenia has an important
genetic component; its heritability is estimated to be between 64% and 81%.3 However,
its mode of inheritance is complex and involves the combination of a variety of genes.
A large, new body of evidence on genetics of schizophrenia has accumulated over recent
years. Many new robustly associated genetic loci have been detected.3 An interesting
development is the identification of a genetic variation in a region on chromosome 11,
which also turns out to be associatedwith schizophrenia.4 This region on chromosome 11
contains the candidate genes activating molecule in beclin-1-regulated gene (AMBRA1),
diacylglycerol kinase zeta gene (DGKZ), muscarinic acetylcholine receptor M4 gene
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(CHRM4) andMidkine (MDK). Genomic location of CHRM4
gene is illustrated in Figure 1. Previous studies have already
linked muscarinic acetylcholine receptors M1 (CHRM1) and
CHRM4 to schizophrenia.5,6 Further findings by Scarr et al
showed that CHRM4 but not CHRM1 expression was
decreased in the caudate-putamen and hippocampus from
patients with this disorder.7
Initially, two muscarinic receptors were distinguished;
termed M1 and M2 (based on selective affinity for
pirenzepine).8 Screening for cDNA or genes homologous
with M1 and M2 revealed the existence of M3, M4, and
M5 receptors.9 The localization and characteristics of human
muscarinic receptor subtype genes are described by Michel
and Teitsma.10 The human M4 receptor gene (CHRM4) con-
sists of a single exon located on chromosome 11p12-p11.2.
Two annotations available from GENCODE and RefSeq,
differ in the size of 5ʹ- and 3ʹ-UTRs but have the same
exon structure (Figure 1).
Muscarinic receptors belong to a family of over
800 G protein-coupled receptors (GPCRs).11,12 Based on the
present knowledge in the brain M2 and M4 receptors interact
with Gi-, Go-, and Gn-type G proteins (all inhibitory vs
adenylate cyclase), while M1, M3 and M5 are coupled to Gq-
type G proteins (activating phospholipase C which catalyzes
the formation of diacylglycerol and inositol triphosphate (IP3)
from phosphatidyl-inositol-4,5-biphosphate (PIP2)).13 Within
the brain CHRM4 levels are particularly high in the dorsal
striatum and relatively low in comparison to cholinergic mus-
carinic M1 receptors (CHRM1) in neocortex, amygdala and
hippocampus.14 From anatomical studies, it can be concluded
that a prominent role of M4 muscarinic receptors is mainly
restricted to the (dorsal) striatum. In addition, within the
striatum the inhibitory CHRM4 are primarily located on pro-
jection neurons constituting the excitatory direct extrapyrami-
dal pathway, while stimulatory CHRM1 are present on
projection neurons constituting the excitatory direct as well
as the inhibitory indirect pathways.15 Hence, activation of
excitatory CHRM1 as well as inhibitory CHRM4 results in a
decrease of behavioral and cognitive output. This data sug-
gests that changes in CHRM4 may be involved in the patho-
physiology of positive and negative schizophrenia
symptoms. According to online resources for research
GeneMANIA database CHRM4 is involved in complicated
genetic networks and pathways with a number of protein
kinases, receptors and translation factors (Figure S1).
In a previous study, Scarr et al made an attempt to deter-
mine whether variations in the CHRM4 gene sequence were
associated with an altered risk of schizophrenia.16 The
CHRM4 gene was studied in 76 schizophrenia patients and
74 persons with no history of psychiatric disorders, and two
genomic variants were identified, rs2067482 and rs72910092.
Of these, only rs2067482, was found to be highly associated
with schizophrenia, further linking CHRM4 to the disorder.
Authors considered cholinergic muscarinic M4 receptor gene
polymorphism not only as a potential risk factor, but also as
a pharmacogenomic marker for schizophrenia. Motivated by
their findings, we aimed to test two hypotheses in larger cohort
of 472 patients with schizophrenia in comparison to 134
healthy controls, ie, whether these 2 SNPs (rs2067482 and
rs72910092) are: 1) potential risk factors for schizophrenia,
and 2) pharmacogenetic markers for antipsychotic-induced
tardive dyskinesia, and discuss their possible significance.
Patients and Methods
Patients
This study was carried out in accordance with the Code of
Ethics of the World Medical Association (Declaration of
Helsinki 1975, revised in Fortaleza, Brazil, 2013), estab-
lished for experiments involving humans. Each patient
provided written informed consent, after the study was
Figure 1 Genomic location of CHRM4 gene. Genomic location of the CHRM4 gene (chr15:46,200,000–47,300,000). Yellow lines highlight the location of two investigated
variants in CHRM4 gene, rs2067482 and rs72910092. PACSIN3 gene is marked by green rectangle.
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approved (protocol N63/7.2014) by the Local Bioethics
Committee of the Mental Health Research Institute.
Patient selection has been previously described.17 We
recruited patients from three psychiatric hospitals located
in the Tomsk, Kemerovo, and Chita oblasts (regions) of
Siberia, Russia. The inclusion criteria were a clinical diag-
nosis of schizophrenia, according to the International
Statistical Classification of Diseases and Related Health
Problems, 10th Revision (ICD-10: F20), and age 18–75
years old. Detailed descriptive statistics are presented
below (Table 1). Exclusion criteria were non-Caucasian
physical appearance or family members (eg, Mongoloid,
Buryats, or Khakassians); pregnancy, or any relevant phy-
sical disorder including organic brain disorders (eg, epi-
lepsy, Parkinson’s disease); or relevant pharmacological
withdrawal symptoms. Clinical examination and diagnos-
tic assessment were carried out using the Positive and
Negative Syndrome Scale (PANSS). The course of schizo-
phrenia (continuous or episodic) was determined by ICD-
10 – in the classification of ICD-10, the fifth character is
used for this. In order to assess the presence or absence of
tardive dyskinesia (TD), patients were assessed according
to the abnormal involuntary movement scale (AIMS).18–20
The AIMS scores were transformed into a binary form
(presence or absence of dyskinesia) with Schooler and
Kane’s criteria.21 Schooler–Kane criteria require: (i) at
least 3 months of cumulative exposure to neuroleptics;
(ii) the absence of other conditions that might cause invo-
luntary movements and (iii) at least moderate dyskinetic
movements in one body area (≥3 on AIMS) or mild
dyskinetic movements in two body areas (≥2 on AIMS).
The presence of orofacial dyskinesia and limb-truncal
dyskinesia was established by a cut-off score of 2 (mild
but definite) on any of the items from 1 to 4 and from 5 to
7 of AIMS, respectively. To compare dosage of antipsy-
chotic medications, all dosages were converted into chlor-
promazine equivalents (CPZeq).22
Healthy Probands
The control group (134 subjects) consisted of mentally and
somatically healthy individuals with Caucasian back-
ground (based on both physical appearance and familial
history) of both genders and aged 19–60 years old, who
provided written informed consent. Exclusion criteria were
chronically physical pathology in exacerbation, relevant
pharmacological withdrawal symptoms, any organic brain
disorders (eg, epilepsy, Parkinson’s disease) or mental
disorders.
DNA Analysis
DNA was isolated from antecubital venous blood sam-
ples by means of a standard phenol-chloroform method.
DNA concentrations were measured with a Thermo
Scientific NanoDrop 8000 UV-Vis Spectrophotometer.
All samples were genotyped without having knowledge
of the patient’s clinical conditions. Genotyping for
rs2067482 and rs72910092 polymorphisms of CHRM4
gene was carried out with the use of the MassARRAY®
System by Agena Bioscience (San Diego, USA), kit
iPLEX Gold 384, in the Laboratory of Genetics of the
University of Groningen. Processing of the DNA sam-
ples included several steps: a standard PCR reaction to
obtain the amplificate, a shrimp alkaline phosphatase
(SAP) reaction to neutralize the unincorporated dNTPs
in the amplificate, the PCR iPLEX Gold extension reac-
tion, followed by placing the samples on a special chip
(SpectroCHIP Array) using NanoDispenser RS1000 and
loading them into the SEQUENOM MassARRAY®
Analyzer 4.
Real-time mass spectrum analysis was conducted with
special program software MassARRAY TYPER 4.0.
Statistical Analysis
Mann–Whitney test was used to compare qualitative traits
and χ2 test was used for categorical traits. Genotype preva-
lence was checked for meeting Hardy–Weinberg equilibrium
expectations by means of χ2 test. Allele and genotype fre-
quencies were compared using χ2 test and Fisher’s exact test,
if necessary. Statistically significant differences were con-
sidered at p<0.05. Odds ratios (ORs) and 95% confidence
intervals (CIs) were calculated when estimating the effect
size of genetic polymorphisms on the risk of schizophrenia
and TD. All statistical analyses were performed using SPSS
for Windows, v. 17. Bonferroni correction for multiple test-
ing was applied to the resulting p values.
Table 1 Characteristics of Schizophrenia and Control Groups
Parameter Schizophrenia Group Control Group
Sex, n (%) Male – 223 (49.7%)
Female – 226 (50.3%)
Male – 62 (46.3%)
Female – 72 (53.7%)
Age, years 41.72 ± 13.315 38.53 ± 12.154
Age of onset, years 26.21 ± 8.975 –
Duration of disease, years 15.60 ± 11.418 –
Dovepress Pozhidaev et al
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Results
After obtaining informed consent, 472 patients with schi-
zophrenia were recruited in total, but only 449 of them
were fulfilling the criterion for tardive dyskinesia (TD) of
receiving the antipsychotic treatment for more than three
months and therefore eligible for the subsequent study
(Table 1).17 [40]. According to the other predefined cri-
teria, 121 out of these 449 patients suffered from TD.
Table 2 presents the frequency of genotypes and alleles
for rs2067482 and rs72910092 polymorphisms of CHRM4
gene in patients with schizophrenia and healthy persons.
The prevalence of genotypes in both the schizophrenia
and healthy groups was consistent with Hardy-Weinberg
equilibrium. The frequency of the С allele of the poly-
morphic variant rs2067482 was significantly higher in
healthy persons compared to patients with schizophrenia
(Table 2; χ2=9.14, p=0.003; OR=0.51, 95% CI [0.33–0.80]).
Accordingly, the CC genotype was found significantly more
often in healthy persons compared to patients with schizo-
phrenia (χ2=9.167, p=0.010; OR=0.49, 95% CI [0.31–0.80]).
We did not reveal any significant contribution of
CHRM4 rs2067482 and rs72910092 to the course of schi-
zophrenia (continuous or episodic) (Table 3).
From the two SNPs studied for CHRM4, only
rs2067482 showed significant association with leading
symptoms of schizophrenia (positive vs negative,
χ2=7.267, p=0.026). The rs2067482*CT (OR=1.63, 95%
CI: 1.04–2.59) genotype was associated with positive lead-
ing symptoms (Table 4).
We did not reveal any statistical differences in the
distribution of genotypes and alleles for rs2067482 and
rs72910092 of CHRM4 between patients with and without
TD (Table 5). In our statistical analysis both rs2067482
and rs72910092 were not linked to neither orofacial nor
limb-truncal TD (Tables S1 and S2).
We did, however, obtain evidence of an association of
rs2067482 with TD in our patient population in compar-
ison with healthy controls (Table 6; χ2=7.42, p=0.02).
Our results could be interpreted in favor of reducing
risk of schizophrenia for carriers of CC genotype and
increasing risk of disease for carriers of CT genotype
respectively (OR=0.45, 95% CI [0.25–0.81]; OR=2.15,
95% CI [1.20–3.86]). Certainly, we have an association
in allelotype (χ2=6.84, p=0.009) and can conclude that
allele C has a possible effect against schizophrenia
(OR=0.50, 95% CI [0.30–0.85] whereas allele T has
a predisposing effect (OR=1.99, 95% CI [1.18–3.37])
towards the disease.
To account for multiple testing, Bonferroni correction
was applied to the resulting p values. The findings in Table
2 stay significant, while in Table 6, only the p value allelic
frequency remains significant.











rs2067482 CC 303 (68.2%) 109 (81.3%) χ1
2 = 0.01
p1 = 0.91
0.49 0.31–0.80 9.167 0.010a
CT 128 (28.8%) 2 (17.9%) 1.86 1.14–3.02




C 0.827 0.903 0.51 0.33–0.80 9.14 0.003a
T 0.173 0.097 1.95 1.26–3.03
rs72910092 CC 413 (92.6%) 127 (94.8%) χ1
2 = 0.66
p1 = 0.42
0.69 0.30–1.60 0.759 0.384
CT 33 (7.4%) 7 (5.2%) 1.45 0.63–3.36




C 0.963 0.974 0.70 0.31–1.60 0.73 0.39
T 0.037 0.026 1.43 0.63–3.28
Note: ap-Values stay significant after Bonferroni correction for multiple testing.
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rs2067482 CC 144 (69.6%) 66 (68.8%) 1.04 0.62–1.75 0.240 0.988
CT 59 (28.5%) 28 (29.2%) 0.97 0.57–1.65
TT 4 (1.9%) 2 (2.1%) 0.93 0.17–5.15
C 0.838 0.833 1.04 0.65–1.64 0.022 0.881
T 0.162 0.167 0.97 0.61–1.53
rs72910092 CC 196 (94.2%) 89 (90.8%) 1.65 0.67–4.06 1.215 0.270
CT 12 (5.8%) 9 (9.2%) 0.61 0.25–1.49
TT 0 (0.0%) 0 (0.0%) – –
C 0.971 0.954 1.62 0.67–3.91 1.171 0.279
T 0.029 0.046 0.62 0.26–1.49










rs2067482 CC 69 (61.6%) 198 (69.2%) 0.71 0.45–1.13 7.267 0.026a
CT 43 (38.4%) 79 (27.6%) 1.63 1.03–2.59
TT 0 (0.0%) 9 (3.1%) 0.13 0.01–2.25
C 0.808 0.830 0.86 0.58–1.28 0.556 0.455
T 0.192 0.170 1.16 0.78–1.73
rs72910092 CC 107 (94.7%) 265 (93.3%) 1.28 0.50–3.29 0.261 0.609
CT 6 (5.3%) 19 (6.7%) 0.78 0.30–2.01
TT 0 (0.0%) 0 (0.0%) – –
C 0.974 0.967 1.27 0.50–3.22 0.346 0.557
T 0.026 0.033 0.76 0.30–1.92
Note: ap-Value denotes statistical significance at the p < 0.05 level.
Table 5 CHRM4 Genotype Distribution in Schizophrenia Patients with and without Tardive Dyskinesia
SNP Genotypes/Alleles With TD Without TD OR χ2 p
Value 95% CI
rs2067482 CC 79 (66.4%) 224 (68.9%) 0.89 0.57–1.39 1.489 0.475
CT 38 (31.9%) 90 (27.7%) 1.22 0.78–1.93
TT 2 (1.7%) 11 (3.4%) 0.49 0.11–2.23
C 0.824 0.828 0.97 0.66–1.44 0.02 0.88
T 0.176 0.172 1.03 0.70–1.52
rs72910092 CC 113 (94.2%) 300 (92.0%) 1.40 0.59–3.31 0.587 0.443
CT 7 (5.8%) 26 (8.0%) 0.71 0.30–1.69
TT 0 (0.0%) 0 (0.0%) – –
C 0.971 0.960 1.38 0.59–3.23 0.56 0.45
T 0.029 0.040 0.72 0.31–1.69
Dovepress Pozhidaev et al
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Discussion
Previously, Scarr et al have found a reduced level of
expression of CHRM4 but not of CHRM1 in the hippo-
campus of schizophrenia patients.7 Thereafter, they
reported the synonymous polymorphism rs2067482 in
CHRM4 to be associated with an increased risk of
schizophrenia.16 In the current study, we have confirmed
an association of the rs2067482 variant with schizophrenia
in 449 patients versus 134 healthy subjects. No difference
in genotype was detected between patients with and with-
out TD. Surprisingly, the results of the allelic association
of the rs2067482 polymorphism with the disease were
opposite to the ones reported earlier: Scarr et al found
allele C being associated with increased risk of
schizophrenia.16 In contrast, our study identified allele
T having higher prevalence in schizophrenia patients
(Table 2). It is hard to explain such inconsistency but
several reasons can be discussed. First, our patient popula-
tion is markedly different from the one Scarr et al studied.
Both populations belong to different ethnical groups
(White Russian vs Australian). Secondly, no data is avail-
able concerning diagnostic subtyping and mental co-
morbidity of their patients which might affect the selection
of the particular individual to the patient group. Moreover,
many patients (exactly half of them in their 2013 study)16
committed suicide, while none of the individuals in our
study had suicidal tendencies, pointing out to different
subtypes/severity of the disease. Thus, CHRM4 may be
involved in anti-suicidal effects and not in schizophrenia
in general. The atypical antipsychotic drug clozapine has
specific activity in preventing suicide attempts in high-risk
patients with schizophrenia or schizoaffective disorder.23
Clozapine is well known to act as a partial agonist at the
CHRM4.24 Moreover, many findings in human and animal
studies indicate an association between cholinergic hyper-
activity and bipolar depression.25,26 The same mechanism,
which in theory might involve insufficient activity of inhi-
bitory CHRM4, might also induce suicidality in patients
with schizophrenia. Therefore, we believe that the findings
of Scarr et al might be related to the specific deceased
patient sample they studied. Furthermore, considering that
schizophrenia affects less than 1% of the population, it
seems quite unlikely that the common allele with the
frequency of 85–95% in the population can be associated
with the disease, as found by Scarr et al.16
We also investigated a possible relationship of
rs2067482 with TD and did not identify any significant
connection. Dyskinesia could be induced by malfunction-
ing of CHRM4 in the dorsal striatum (particularly
putamen).27 However, as adaptation of the activity of
direct and indirect extrapyramidal pathways is one of the
major functions to regulate motor activity, a genetically
induced CHRM4 functionality could be compensated dur-
ing development. Nevertheless, the relatively high level of
expression of CHRM4 in ventral and dorsal striatum in
comparison to amygdala and hippocampus,14 makes it
difficult to attribute much importance to dysfunction of
CHRM4 within the latter region as suggested by Scarr
et al.7 A well-known theory holds that in schizophrenia
delusions are caused by aberrant salience (function of the
amygdala) resulting from dopaminergic hyperactivity
(function of the midbrain).28,29 We have argued that the
primary mechanism could also be the other way around
meaning that dysfunction of amygdala and hippocampus
Table 6 CHRM4 Genotype Distribution in Schizophrenia Patients with Tardive Dyskinesia and Healthy Persons
SNP Genotypes/Alleles Schizophrenia Patients with TD Healthy Persons OR χ2 p
Value 95% CI
rs2067482 CC 79 (66.4%) 109 (81.3%) 0.45 0.25–0.81 7.42 0.02a
CT 38 (31.9%) 24 (17.9%) 2.15 1.20–3.86
TT 2 (1.7%) 1 (0.7%) 2.27 0.20–25.40
C 0.824 0.903 0.50 0.30–0.85 6.84 0.009b
T 0.176 0.097 1.99 1.18–3.37
rs72910092 CC 113 (94.2%) 127 (94.8%) 0.89 0.30–2.61 0.05 0.98
CT 7 (5.8%) 7 (5.2%) 1.12 0.38–3.30
TT 0 (0.0%) 0 (0.0%) – –
C 0.971 0.974 0.89 0.31–2.58 0.04 0.83
T 0.029 0.026 1.12 0.39–3.24
Notes: ap-Value denotes statistical significance at the p < 0.05 level. bp-Value stays significant after Bonferroni correction for multiple testing.
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results in activation of monoaminergic centers of the mid-
brain which activate circuits regulating pleasure and
happiness.30 This would place the suggestion by Scarr
et al7 about altered CHRM4 expression in hippocampus
of patients with schizophrenia in another perspective.
Further study of the role of CHRM4 for the activity of
fibres originating within amygdala and hippocampus and
projecting to ventral striatum31 and/or via the habenula to
monoaminergic midbrain centers32 is of potential interest
to explain delusional symptoms of schizophrenia.30
Scarr et al did not report finding any de novomutations in
the CHRM4 gene neither in patients nor in controls.16 Out of
eight common variants reported for the gene, they only found
two (rs2067482 and rs72910092), and only the first one was
shown to be associated with schizophrenia (albeit at the
border of significance). However, although there is enough
evidence that the CHRM4 gene itself might be involved in
schizophrenia, no direct link exists between rs2067482 and
the gene. Polymorphism rs2067482 does not cause amino
acid change in the protein sequence but the option still
remains that it has a regulatory effect on gene expression.
GTEx portal search (gtexportal.org) reveals 300eQTL SNPs
associated with CHRM4 expression. Variant rs72910092
does not appear in that list as well as it is not a significant
eQTL for any other gene. In contrast, rs2067482 is found to
be a significant eQTL forCHRM4 (P value 1.4 x 10−4) in skin
tissue. In addition, rs2067482 is also found to be eQTL for 10
more protein coding genes, namely AMBRA1, ARFGAP2,
ARHGAP1, ATG13, C11orf49, DDB2, LRP4, MADD, MDK
and PACSIN3 (PACSIN3 is the only gene with association
found in brain cerebellum). Therefore, it is possible that the
association of rs2067482 with schizophrenia is via its regu-
latory effect on CHRM4 and/or another gene. In the original
GWA study, which identified chr11p11.2 locus association
with schizophrenia,4 four highly correlated SNPs
(rs7112229, rs11819869, rs7130141 and rs12575668) were
found. In GTEx, these SNPs are significant eQTLs for the
genes ACP2, AMBRA1, ARFGAP2, ARHGAP1, ATG13,
C11orf49, CHRM4, DDB2, LRP4, MADD, MDK and
PACSIN3. Of those, only one association is found in brain,
namely PACSIN3 (in cerebellum). Interestingly, linkage dis-
equilibrium analysis with LDlink (ldlink.nci.nih.gov) shows
that rs2067482 and four schizophrenia variants from GWAS
are not highly linked (r2 0.35 to 0.57), suggesting indepen-
dent regulation of the target genes. Moreover, this analysis
identifies PACSIN3 as the common gene regulated by all
(described above) genomic variants in the brain. PACSIN3
is a member of pacsins family of cytoplasmic adapter
proteins. Three members of the family are found to date,
with high sequence conservation, and involved in
endocytosis33 and actin dynamics.34 PACSIN3 is not a well-
studied gene; it plays a key role in the embryonic morpho-
genesis that has been demonstrated in the PACSIN3 knockout
zebrafish model.35 Pacsin1 knock-out in mice results, among
other defects, in tonic-clonic seizures, suggesting pacsins
involvement in brain functioning.36
According to the Gene network constructed through the
online resource for research GeneMANIA (Figure S1)
PACSIN3 is interconnected with CHRM4 via EEF1A2.
Eukaryotic elongation factor 1, alpha-2 (eEF1A2) protein
is involved in protein synthesis, suppression of apoptosis,
and regulation of actin function and cytoskeletal structure.
EEF1A2 gene is highly expressed in the central nervous
system and EEF1A2 knockout mice show neuronal
degeneration.37 Mutations in EEF1A2 have been recently
shown to cause epileptic encephalopathy associated with
neurodevelopmental disorders such as intellectual disabil-
ity, autistic spectrum disorder, hypotonia and dysmorphic
facial features.38
Our study has three limitations. 1) The sample size of
the control group is not large enough although the minor
allele frequency (MAF) for rs2067482 in our control group
is 9.7%, which is close to MAF 11% according to the 1000
Genomes Project; 2) Despite the fact that we tried to select
individuals of only Caucasian background, in the popula-
tion of the given region of Siberia a national admixture
driving these results is possible; 3) It is possible that
rs2067482 is in high linkage disequilibrium with another
SNP that does increase the risk of schizophrenia. This is
quite common especially when several studies give con-
flicting results, as it is appears to be the case in current
study. In prospect, it would have been helpful to evaluate
the entire LD region surrounding CHRM4 and test the
tagging SNPs in the LD region.
Conclusion
To sum up, our findings confirm association of rs2067482
polymorphism with schizophrenia. However, current data
does not support the hypothesis that this link is via the
regulation of the CHRM4 gene. Rather than CHRM4,
combined evidence from our and previous studies suggests
PACSIN3 might be regulated by rs2067482 and identifies
PACSIN3 as a novel candidate gene for schizophrenia.
There are no de novo mutations in CHRM4 in schizophre-
nia patients and all regulatory variants, which were
described earlier, point to different target genes. In
Dovepress Pozhidaev et al
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addition, we can speculate that decreased level of CHRM4
in schizophrenic patients was a consequence, but not
a cause of illness. There is enough evidence that the
reduction in CHRM4 gene expression contributes to the
course of the disease, it is however unlikely that CHRM4
is a causative gene. Nevertheless, our data demonstrate the
link between the CHRM4 locus and schizophrenia, and
indicate a need for further research on the role of this
gene in the pathogenesis of the disease.
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